EIZO (6737) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
31 Jul, 2026Executive summary
Net sales for the three months ended June 30, 2026, rose 15.5% year-over-year to JPY 20,031 million, driven by strong overseas performance and favorable exchange rates, especially the weaker yen against the euro.
Operating profit reached JPY 807 million, reversing a prior-year loss, and net income rose to JPY 1,215 million, up JPY 0.9 billion YoY.
Gross profit margin improved by 1.0 percentage point to 34.6%, aided by higher sales and forex impacts.
Financial highlights
Net sales: JPY 20.0 billion (115.5% YoY); gross profit: JPY 6.9 billion (118.8% YoY); gross margin: 34.6% (+1.0pt YoY).
Operating profit: JPY 0.8 billion (up from a loss of JPY 97 million YoY); operating margin: 4.0% (+4.6pt YoY).
Ordinary profit: JPY 1.6 billion (up 129.0% YoY); net income: JPY 1.2 billion (up 394.7% YoY).
SG&A expenses increased to JPY 6.1 billion, mainly due to forex effects.
Basic earnings per share for the quarter were JPY 30.76, up from JPY 7.48 a year earlier.
Outlook and guidance
Full-year forecast for fiscal year ending March 31, 2027: net sales of JPY 85,000 million (up 4.5% YoY), operating profit of JPY 3,300 million (up 39.5%), and net income of JPY 6,500 million (down 11.2%).
No revision to FY26/FY27 guidance or dividend forecasts as of May 12, 2026.
Foreign exchange sensitivity: JPY 1 depreciation impacts operating income by JPY 80 million (USD, negative) and JPY 100 million (EUR, positive).
Latest events from EIZO
- Profit attributable to owners surged 76.5% year-over-year on stable sales and investment gains.6737
Q4 202612 May 2026 - Profits fell on weak demand, but full-year growth and a share split are forecast.6737
Q1 202518 Mar 2026 - Profits and comprehensive income fell sharply, with a modest sales outlook and share split enacted.6737
Q2 202518 Mar 2026 - Profits dropped despite stable sales, with unchanged guidance and a recent share split.6737
Q3 202518 Mar 2026 - Flat sales and lower profit, but FY2026 outlook targets growth and higher dividends.6737
Q4 202518 Mar 2026 - Sales and profits fell on European weakness, but margin and new products support future outlook.6737
Q1 202618 Mar 2026 - Healthcare and Amusement drove 2.9% sales growth, but profits were pressured by higher SG&A.6737
Q2 202618 Mar 2026 - Net sales rose, but profit outlook was cut due to higher costs and weak European demand.6737
Q3 202618 Mar 2026